Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, with a cumulative rise of over 200% in the past four weeks, indicating strong market interest and potential investor confidence in the company's strategic initiatives [1] Group 1: Strategic Developments - On July 30, Huajian Medical announced a strategic cooperation framework agreement with BGI Genomics to establish the "Huajian BGI Win-Win Innovation Drug Intellectual Property Tokenization Fund" [1] - The fund will invest in Huajian Medical's "NewCo+RWA" Web3 exchange ecosystem projects in regions including Hong Kong and the United States [1] - BGI Win-Win, initiated by BGI Genomics, is a corporate venture capital entity with extensive experience and resources in the innovative medical and drug sectors [1] Group 2: Market Positioning - The company is developing a Web3 exchange ecosystem named "IVDNewCo Exchange" aimed at addressing critical pain points in the pharmaceutical industry, particularly the lengthy and costly drug development process [1] - The solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates using RWA technology [1] - The goal is to position itself as the "Nasdaq + Uniswap" of the medical RWA sector, ensuring compliance while achieving decentralized liquidity [1]
华检医疗盘中再涨9% 近四周累涨200% 携手华大共赢建立创新药RWA专属基金